Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic
paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target …

Targeting the “undruggable” proteome remains one of the big challenges in drug discovery.
Recent innovations in the field of targeted protein degradation and manipulation of the …

Summary The ClpC1: ClpP1P2 protease is a core component of the proteostasis system in
mycobacteria. To improve the efficacy of antitubercular agents targeting the Clp protease …

The rapid and ever-growing advancements from within the field of proteolysis-targeting
chimeras (PROTAC)-induced protein degradation have driven considerable development to …

Protein silencing is often employed as a means to aid investigations in protein function and
is increasingly desired as a therapeutic approach. Several types of protein silencing …

Targeted protein degradation (TPD) technology has gradually become widespread in the
past 20 years, which greatly boosts the development of disease treatment. Contrary to small …

The vast majority of currently marketed drugs rely on small molecules with an 'occupancy-
driven'mechanism of action (MOA). Therefore, the efficacy of these therapeutics depends on …

Targeted protein degradation mediated by small molecule degraders represents an exciting
new therapeutic opportunity to eliminate disease-causing proteins. These molecules recruit …

The treatment measures of malignant carcinomas are most important for human health. In
recent years the use of targeted therapy based on small molecule compounds and identical …

The emergence of PROTACs as a transformative class of therapeutic agents has prompted
an intense investigation into their potential role in breast cancer. This chapter consolidates …